Upgrading Environmental Monitoring Through Biofluorescent Particle Counting

Environmental monitoring programmes in pharmaceutical cleanrooms were built around intermittent sampling and delayed culture results, yet modern manufacturing demands real-time understanding of microbial risk. As contamination control strategies evolve toward prevention rather than retrospective investigation, biofluorescent particle counters have emerged as a powerful upgrade to traditional viable monitoring. By delivering immediate biological insight alongside conventional particle data, technologies such as the BioAerosol Monitoring System (BAMS) are transforming how manufacturers detect, investigate and control contamination in both critical and routine cleanroom environments.

Introduction: Why Traditional Viable Monitoring Is No Longer Enough

Environmental monitoring has always served as a foundation of contamination control in pharmaceutical manufacturing. Air sampling, settle plates and surface monitoring have historically provided the primary means of assessing microbial cleanliness in controlled environments. These methods remain essential for regulatory compliance, organism identification and long-term trending. However, they were developed in and for an era that relied on periodic verification rather than the continuous process understanding desired in modern manufacturing.

Culture-based monitoring inherently provides delayed information. Samples must be collected at defined intervals, transported to the laboratory and incubated for several days before interpretation. By the time results are available, the production activity that generated the contamination event has already occurred. Investigations are therefore reactive, relying on historical reconstruction rather than real-time observation.

In addition to the delay, traditional viable monitoring captures only isolated snapshots of cleanroom conditions. Even with robust sampling programmes, the vast majority of manufacturing time remains unmonitored. Transient contamination events, short-duration airflow disruptions or momentary operator interventions may never be detected through scheduled culture sampling alone. Modern pharmaceutical manufacturing has outgrown this approach. The rise of high-value biologics, cell and gene therapies and complex aseptic filling operations has dramatically increased the risk and cost associated with microbial contamination. A single excursion can result in significant product loss, extended downtime, regulatory scrutiny and patient risk.

Regulatory guidance has evolved accordingly. Current expectations emphasise proactive contamination control strategies, continuous process understanding, early detection of risk and data-driven environmental control, particularly in critical Grade A zones. Rather than relying solely on delayed confirmation, manufacturers are now expected to understand and control contamination pathways in real time. This shift has driven the increasing adoption of rapid and continuous monitoring technologies. Among the most impactful of these advancements is biofluorescent particle counting, which provides real-time insight into biological particle behaviour within cleanroom environments.

Understanding the Science Behind Biofluorescent Particle Counting

Traditional non-viable particle counters rely on light scattering to determine particle size and concentration. While these measurements are critical for assessing overall cleanroom performance, they offer no information about whether particles are biological in nature. A dust particle, fibre, skin fragment or microorganism will all be counted equally based solely on size. Biofluorescent particle counters build upon this foundation by introducing intrinsic fluorescence detection. Using a laser excitation source, typically around 405 nm, BFPC systems illuminate each airborne particle as it passes through the optical sensing region. Two signals are generated simultaneously. The first signal arises from scattered light, which is proportional to particle size and enables classification across standard cleanroom particle channels. The second signal originates from fluorescence emitted by naturally occurring biological compounds within microbial cells.

Many microorganisms contain intrinsic fluorophores such as nicotinamide adenine dinucleotide (NADH), riboflavin and, in some species, dipicolinic acid. When excited by violet or ultraviolet light, these molecules emit characteristic fluorescence that can be detected optically.[1]

By capturing both scatter and fluorescence signals for each particle, BFPCs can differentiate biologically derived particles from inert environmental debris in real time. This allows real-time enumeration of viable biological particle trends rather than relying solely on indirect culture confirmation.

It is important to note that BFPC systems do not measure microbial growth or colony formation. Instead, they detect intrinsic biological fluorescence, typically reported as autofluorescence units. These values represent biological particle presence rather than culturable organisms. Studies have shown that AFU measurements provide a broader representation of total viable and viable-but-nonculturable microbial burden, offering earlier indication of contamination events compared to culture methods alone.[2] This fundamental difference explains why BFPC data should not be interpreted as a 1:1 replacement for CFU counts. Rather, they serve as real-time biological trending tools that complement traditional microbiology.

Why Real-time Biological Trending Changes Contamination Control

The most transformative aspect of BFPC technology is not simply

faster results, but the shift from intermittent verification to continuous environmental awareness.

In traditional monitoring programmes, viable samples may be collected a few times per shift or per day. Between those sampling points, the environment remains effectively invisible. Any transient contamination events, short-duration airflow disruptions or momentary lapses in aseptic technique may go completely undetected. BFPC systems can generate real-time data throughout cleanroom operation. Every minute of production becomes a monitored period, producing thousands of data points that reveal how biological particle levels fluctuate in response to real activities.

This real-time visibility allows manufacturers to:

- Observe microbial risk during specific process steps
- Correlate contamination trends with operator interventions
- Identify high-risk activities and zones
- Detect abnormal patterns before excursions occur
- Strengthen contamination control strategies based on real data

Instead of asking "What happened three days ago?", cleanroom teams can see contamination as it occurs and respond immediately. This capability significantly improves root cause investigations. Rather than reconstructing events from limited historical data, investigators can analyse real-time trends tied directly to specific activities, personnel movements or airflow changes. This type of trending also supports long-term process optimisation. Manufacturers can evaluate procedural changes, training effectiveness, engineering modifications and cleaning strategies based on their real-time impact on biological particle levels.

Regulatory Alignment with Real-Time Monitoring Approaches

Regulatory bodies increasingly support the integration of rapid and alternative microbiological methods as part of modern contamination control strategies.

The revised EU GMP Annex 1 places strong emphasis on proactive contamination prevention, continuous monitoring where appropriate and enhanced process understanding in sterile manufacturing environments.[3] The guidance encourages manufacturers to adopt technologies that improve early detection of contamination risk rather than relying solely on retrospective confirmation. Similarly, USP <1223> and European Pharmacopoeia 5.1.6 establish formal frameworks for validating alternative microbiological methods, including real-time technologies such as BFPCs, provided they demonstrate acceptable performance compared to conventional methods.[4,5] Industry guidance documents such as PDA Technical Report 33 further support the use of rapid microbiological methods to improve contamination control and process understanding.[6] Together, these regulatory developments reflect a broader industry shift toward real-time environmental insight as a critical component of modern pharmaceutical manufacturing.

Practical Deployment of BFPC Technology in Cleanroom Environments

While the scientific principles of BFPC technology are well established, successful implementation in pharmaceutical cleanrooms requires instrumentation specifically designed for regulated environments.

The BioAerosol Monitoring System (BAMS) represents a BFPC platform developed to meet cleanroom operational and regulatory needs. The BAMS measures particles across standard cleanroom size channels from 0.5 microns to 25 microns while simultaneously identifying biological particles through fluorescence. Each airborne particle is analysed individually, producing real-time data streams for both total particulate burden and viable biological particle trends. This dual output allows direct correlation between conventional particle cleanliness metrics and microbial risk indicators within the same monitoring system.

To support diverse monitoring objectives, the BAMS is available in both portable and remote configurations.



Figure 1: Portable BAMS

Portable BAMS for General Environmental Monitoring and Investigations

The Portable BAMS (Figure 1) was developed to bring real-time viable particle monitoring directly into cleanroom operations without the constraints of fixed installation. By combining intrinsic fluorescence detection with traditional particle sizing at a controlled pharmaceutical-standard flow rate of 2.83 LPM, the system allows contamination control teams to assess biological particle behaviour wherever insight is needed.

In practice, the Portable BAMS functions as a real-time diagnostic tool for cleanroom environments. Instead of waiting several days for culture-based results, teams can observe how biological particle levels respond immediately to specific activities, environmental conditions and process steps.

One of the most impactful applications is root cause investigation following microbial excursions (Figure 2). When elevated CFU results are identified through traditional monitoring, the Portable BAMS can be deployed in the affected area to assess microbial risk during routine operations. This often reveals short-duration contamination events associated with operator movement, gowning behaviours, material transfers, equipment interaction or airflow disruption that are rarely captured by intermittent culture sampling alone.



Figure 2: BFPCs for Investigations

Additional common applications include:

- General real-time environmental monitoring in replacement of or as a complement to traditional methodology
- Assessing the microbial impact of new equipment and processes
- Evaluating aseptic technique during operator training
- Monitoring manual interventions and line clearances
- Investigating transient contamination events
- Supporting contamination control strategy development

By providing immediate biological insight, the Portable BAMS significantly shortens investigation cycles and enables data-driven process improvements that are difficult to achieve through traditional monitoring alone.

The Remote BAMS for Fixed Monitoring in Critical Grade A Environments

While portable instruments offer flexibility for investigations and process understanding, continuous monitoring within critical zones requires permanent device integration designed for controlled environments.

The Remote BAMS (Figure 3) was specifically developed for fixed installation in isolators, RABS and Grade A processing zones where real-time microbial risk awareness is most critical. Its compact footprint allows placement within tight enclosure spaces while preserving airflow integrity and pressure balance. The Remote BAMS offers the same technological basis as the Portable BAMS but also delivers fixed and continuous viable particle trending alongside conventional particle size data. This ensures a consistent monitoring approach across both investigative and critical-zone applications. This device can be connected to existing central vacuum systems or operated using closed-loop external blower control, allowing facilities to integrate real-time monitoring without disrupting enclosure performance or cleanroom airflow dynamics.

In critical Grade A environments, the Remote BAMS provides continuous visibility into microbial risk throughout every production run. Rather than relying solely on periodic viable air samples, manufacturers gain uninterrupted biological trend data that captures transient contamination events, operator interactions and process-related fluctuations.

Key benefits within critical zones include:

- Immediate detection of biological particle spikes
- Real-time trend analysis during production activities
- Improved understanding of intervention-related risk
- Strong support for contamination control strategies
- Enhanced data for investigations and regulatory review

Figure 3: Remote BAMS

This level of continuous insight is particularly valuable in isolator systems, where brief glove manipulations, material transfers or airflow disturbances can generate contamination events that may never coincide with scheduled culture sampling. By transforming Grade A monitoring from intermittent confirmation to continuous biological awareness, the Remote BAMS strengthens contamination prevention rather than relying solely on post-event detection.

Integrating Real-Time Monitoring with Culture-Based Confirmation Using Gelatine Filters

While real-time biofluorescent monitoring provides immediate insight into biological particle trends, culture-based methods remain essential for microbial identification, speciation and regulatory documentation.

To support this requirement, the Remote BAMS can be paired with an external gelatine filter sampling system positioned within the same sampled airstream as the biofluorescent measurement. This ensures that both real-time biological trending and culture recovery represent identical environmental exposure.

When abnormal biological trends or alerts are observed, the gelatine filter can be aseptically removed and incubated using standard microbiological methods. Resulting colonies can then be identified to species level and incorporated into routine environmental monitoring investigations. Rather than choosing between rapid monitoring and traditional culture methods, manufacturers gain a comprehensive contamination control strategy that combines early detection with defensible confirmation.

Comprehensive Validation of BAMS in Regulated Pharmaceutical Environments

Successful implementation of real-time viable monitoring requires extensive validation to demonstrate equivalency, reliability and suitability within regulated environments. The BAMS platform has undergone a comprehensive validation programme addressing both optical biofluorescent detection performance and culture-based recovery using gelatine filters.

Validation of Real-Time Biofluorescent Monitoring Performance

The BAMS was validated following the principles outlined in USP <1223>, European Pharmacopoeia 5.1.6 and industry guidance for alternative microbiological methods. Testing was conducted using the Andersen six-stage impactor as the reference method across multiple representative microorganisms, including Gram-positive bacteria, Gram-negative bacteria, bacterial spores, yeasts and moulds.

Key performance characteristics evaluated included:

- Accuracy relative to traditional CFU-based sampling
- Precision and repeatability
- Linearity across a wide concentration range
- Specificity for biological particles
- Limits of detection and quantification
- Robustness under varying environmental conditions

Results demonstrated strong agreement between BAMS biofluorescent counts and reference culture methods, with



Figure 4: USP 1223 Accuracy Results Summary

recovery (Figure 4), precision and detection sensitivity exceeding acceptance criteria for quantitative equivalency.

Collectively, these results support the suitability of BAMS as a validated alternative microbiological monitoring technology in regulated pharmaceutical environments.

Validation of Gelatine Filter Integration for Culture Confirmation

Dedicated validation studies were also conducted to evaluate the performance of the external gelatine filter system when used in conjunction with the Remote BAMS during continuous monitoring.

These studies assessed:

- Gelatine filter stability and microbial viability over extended sampling durations (Figure 5)
- The impact of tubing length, bends and routing geometry on CFU recovery
- Consistency of microbial capture under realistic installation conditions.



Figure 5: Gelatine Filter Stability Validation Results

Results demonstrated reliable and consistent culture recovery across time-based sampling scenarios and representative installation configurations. Internal particle data confirmed comparable aerosol loading between test conditions, supporting accurate interpretation of CFU results.

This validation confirms that real-time biofluorescent monitoring can be seamlessly integrated with traditional culture-based microbiology without compromising recovery or regulatory expectations.

The Evolving Future of Cleanroom Environmental Monitoring
As pharmaceutical manufacturing continues to advance, the limitations of intermittent culture-based monitoring become increasingly apparent. Modern contamination control strategies demand continuous insight, rapid response and data-driven decision making.

Biofluorescent particle counters offer a practical and scientifically robust solution by delivering:

- Real-time biological trend awareness
- Early detection of contamination risk
- Improved root cause investigations
- Stronger contamination control strategies
- Seamless integration with traditional microbiology

Portable BFPC systems support flexible investigations and process understanding, while fixed remote installations provide continuous monitoring within critical Grade A environments. Together, these approaches represent a meaningful evolution of environmental monitoring programmes, shifting cleanroom control from delayed confirmation toward proactive contamination prevention. By combining real-time biological insight with established microbiological practices, BFPC technology positions pharmaceutical manufacturers to meet modern regulatory expectations while improving product safety, operational efficiency and contamination control in increasingly complex manufacturing environments.

REFERENCES

1. Cabredo S, Parra A, Anzano J. Bacteria spectra obtained by laser induced fluorescence. Journal of Fluorescence, 17(2), 171–180 (2007).
2. Salvas J, Merker P, Dingle M et al. Understanding the non equivalency of biofluorescent particle counts versus the colony forming unit. PDA Journal of Pharmaceutical Science and Technology, 77(6), 514–518 (2023).
3. European Commission. EU GMP Annex 1: Manufacture of sterile medicinal products (2022).
4. United States Pharmacopeia. Validation of Alternative Microbiological Methods <1223>.
5. European Pharmacopoeia. 5.1.6 Alternative methods for control of microbiological quality.
6. Parenteral Drug Association. Technical Report No. 33: Evaluation, validation, and implementation of alternative and rapid microbiological methods.

Christine Troutman

Christine Troutman is the Director of Scientific Operations at MicronView, where she leads product validation, regulatory alignment and scientific strategy for bioaerosol and particle monitoring technologies used in pharmaceutical cleanrooms worldwide. With a background in microbiology, she focuses on advancing real-time contamination control solutions and supporting manufacturers in modernising environmental monitoring programmes.

Email: c.troutman@micronview.com